Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Rituximab in non-Hodgkin's lymphoma pivotal trial: infections

From: B cell non-Hodgkin's lymphoma: rituximab safety experience

Patients monitored throughout treatment and >1 year follow up

Despite B cell depletion, incidence of infection was not increased

Most infections were typical of those common in normal hosts

Predominantly bacterial

Seven episodes of grade 3 infections

No patients experienced grade 4 infections

  1. Data from McLaughlin and coworkers [1].
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us